
Avid Bioservices (CDMO) Stock Forecast & Price Target
Avid Bioservices (CDMO) Analyst Ratings
Bulls say
Avid Bioservices Inc. demonstrates strong growth potential due to ongoing capacity expansions that are expected to more than double its revenue-generating capabilities within the next three years. The company's existing facilities offer significant opportunities for expansion, which is anticipated to generate high incremental margins, supporting a projected double-digit revenue compound annual growth rate (CAGR) and meaningful EBITDA margin expansion. Additionally, improvements in bookings momentum contribute positively to the overall demand outlook, further solidifying Avid's revenue guidance for fiscal year 2025 and enhancing visibility into its longer-term growth prospects.
Bears say
Avid Bioservices is facing several fundamental challenges that contribute to a negative outlook on its stock. The company's recent revenue miss, coupled with higher-than-expected selling, general, and administrative expenses resulting in a shortfall in EBITDA, indicates a trend of operational difficulties, particularly in the contract development and manufacturing organization (CDMO) segment. Additionally, external factors such as potential customer insourcing, a pullback in biotech funding, and intense competition raise concerns about revenue stability and growth, threatening the company's long-term profitability.
This aggregate rating is based on analysts' research of Avid Bioservices and is not a guaranteed prediction by Public.com or investment advice.
Avid Bioservices (CDMO) Analyst Forecast & Price Prediction
Start investing in Avid Bioservices (CDMO)
Order type
Buy in
Order amount
Est. shares
0 shares